Show simple item record

dc.contributor.authorOkonkwo, Rose I.
dc.contributor.authorWeidmann, Anita Elaine
dc.contributor.authorEffa, Emmanuel E.
dc.date.accessioned2017-04-06T11:45:07Z
dc.date.available2017-04-06T11:45:07Z
dc.date.issued2015-12-21en
dc.identifier.citationOKONKWO, R.I., WEIDMANN, A.E. and EFFA, E.E. 2016. Renal and bone adverse effects of a tenofovir-based regimen in the treatment of HIV-Infected children: a systematic review. Drug safety [online], 39(3), pages 209-218. Available from: https://doi.org/10.1007/s40264-015-0371-z.en
dc.identifier.issn0114-5916en
dc.identifier.issn1179-1942en
dc.identifier.urihttp://hdl.handle.net/10059/2259
dc.description.abstractIntroduction - Tenofovir disoproxil fumarate (TDF)-containing regimens in the treatment of HIV-infected children have safety concerns with respect to renal and bone toxicity. Objective - The aim of this study was to systematically review and critically appraise the literature relating to the reported renal and bone adverse effects of TDF-based regimens in the treatment of HIV-infected children from 2 to 19 years old. Methods - Searches were performed using the Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), MEDLINE, OvidSP, ScienceDirect and Web of Science databases and platforms. All primary studies involving tenofovir use in HIV-infected children were sought. Studies that involved the use of TDF for pre- and post-exposure prophylaxis, and treatment of chronic hepatitis B virus infection were excluded. Data on study characteristics, participant's characteristics, therapeutic intervention and adverse effects were extracted using a piloted tool. In addition, pharmacovigilance data from the WHO Adverse Reaction database were included. Results - We identified 19 studies that reported the presence of renal and bone adverse effects of TDF and these included a total of 1100 study participants. The reports were in distinctly heterogeneous participant groups. A total of 287 renal and bone adverse effects were reported (250 renal and 37 bone adverse effects). Approximately 238 (21.6 %) participants were affected by these adverse effects. Of these, 15 participants stopped their TDF-containing regimen due to these adverse effects. In addition, the pharmacovigilance data from the WHO Adverse Reaction database reported 101 renal and bone adverse effects for patients whose indication was HIV/AIDS. Conclusion - This systematic review summarises the reports of renal and bone adverse effects of a TDF-containing regimen in the treatment of HIV-infected children. Our findings suggest that the benefits of using TDF in children need to be balanced against the potential risk of toxicity.en
dc.language.isoengen
dc.publisherSpringeren
dc.rightshttps://creativecommons.org/licenses/by-nc/4.0en
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectRenal and bone toxicityen
dc.subjectHIV infecteden
dc.subjectChildrenen
dc.titleRenal and bone adverse effects of a tenofovir-based regimen in the treatment of HIV-Infected children: a systematic review.en
dc.typeJournal articlesen
dc.publisher.urihttps://doi.org/10.1007/s40264-015-0371-zen
dcterms.publicationdate2016-03-01en
refterms.accessExceptionNAen
refterms.dateDeposit2017-04-06en
refterms.dateEmbargoEnd2016-12-21en
refterms.dateFCA2017-04-06en
refterms.dateFCD2017-04-06en
refterms.dateFreeToDownload2017-04-06en
refterms.dateFreeToRead2017-04-06en
refterms.dateToSearch2017-04-06en
refterms.depositExceptionNAen
refterms.panelAen
refterms.technicalExceptionNAen
refterms.versionAMen
rioxxterms.publicationdate2015-12-21en
rioxxterms.typeJournal Article/Reviewen
rioxxterms.versionAMen


Files in this item

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0